<DOC>
	<DOC>NCT00036166</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.</brief_summary>
	<brief_title>Study of FK463 for the Treatment of Invasive Aspergillosis</brief_title>
	<detailed_description>This will be an open-label, non-comparative study of intravenous FK463. Enrollment will include at least 100 patients evaluable for efficacy.</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<criteria>Inclusion Criteria Has proven or probable systemic infection with Aspergillus species Exclusion Criteria Has abnormal liver test parameters, e.g., AST or ALT &gt; 10 times upper limit of normal Has bronchopulmonary aspergillosis, aspergillomas, sinus aspergillosis or external otitis but does not have histologic evidence of tissue invasion Has lifeexpectancy judged to be less than 5 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Aspergillus</keyword>
	<keyword>Anti-Fungal</keyword>
</DOC>